Interestingly, an HSP70 inhibitor exerts potent anti-tumor effects on the ABC-DLBCL cells in vitro and in xenografting models by restoring the nuclear accumulation of the unstable Blimp-1 mutants, thus suggesting that it may be a promising therapeutic in the clinical management of the specific ABC-DLBCL cases that express N-terminal misfolded and unstable Blimp-1 mutants. Here, PRDM1 is linked to aneurysmal bone cyst.